- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...BioAge Halts Phase 2 Obesity Study Just Two Months After IPO
BioAge Labs, a recent success in the biotechnology IPO market, has made a surprising decision to discontinue its phase 2 obesity study, just weeks...Novartis Shells Out $1B Upfront to PTC For Midphase Huntington Program
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutics' mid-phase Huntington's disorder study, facilitating the biotech's swift turnaround from unsatisfactory...
- Commercial
Portage packages Tarus’ adenosine receptor antagonists into new business
Over two years after taking over Tarus Therapeutics, Portage Biotech is reintroducing Tarus’ adenosine receptor antagonists through a new company headed by a previous...SiteOne Therapeutics Secures $100 Million to Advance Non-Opioid Painkiller Development
Mohsin Riaz - 0Fifteen years ago, as concerns about the growing opioid crisis began to emerge, a Maryland-based company, SiteOne Therapeutics, was founded with the aim of...Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drug Facility in Denmark
Danish pharmaceutical giant Novo Nordisk announced plans to invest 8.5 billion Danish crowns ($1.2 billion) in a new facility in Odense, Denmark, dedicated to...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...BioAge Halts Phase 2 Obesity Study Just Two Months After IPO
BioAge Labs, a recent success in the biotechnology IPO market, has made a surprising decision to discontinue its phase 2 obesity study, just weeks...Novartis Shells Out $1B Upfront to PTC For Midphase Huntington Program
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutics' mid-phase Huntington's disorder study, facilitating the biotech's swift turnaround from unsatisfactory...
- Commercial
Portage packages Tarus’ adenosine receptor antagonists into new business
Over two years after taking over Tarus Therapeutics, Portage Biotech is reintroducing Tarus’ adenosine receptor antagonists through a new company headed by a previous...SiteOne Therapeutics Secures $100 Million to Advance Non-Opioid Painkiller Development
Mohsin Riaz - 0Fifteen years ago, as concerns about the growing opioid crisis began to emerge, a Maryland-based company, SiteOne Therapeutics, was founded with the aim of...Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drug Facility in Denmark
Danish pharmaceutical giant Novo Nordisk announced plans to invest 8.5 billion Danish crowns ($1.2 billion) in a new facility in Odense, Denmark, dedicated to...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Denali-Sanofi’s ALS Candidate Falls Short in Mid-Stage Study
Denali and Sanofi have been working together since 2018, when they reached...
Life Sciences Voice Top Five Newsletter- March 2023
This week we take a look at FDA’s approval for the first...
Moderna’s Flu Shot Struggles to Clear Phase 3 Trial
Moderna has stated that the company's first-ever seasonal flu vaccine has not...
Must Read
Portage packages Tarus’ adenosine receptor antagonists into new business
Over two years after taking over Tarus Therapeutics, Portage Biotech is reintroducing Tarus’ adenosine...
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a...
FDA Lays Out Guidelines Regarding Pulse Oximeter Accuracy Across Skin Tones
To assist in ensuring that pulse oximeters function appropriately across all skin tones, the...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com